Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Inc (XFOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 104,255
  • Shares Outstanding, K 170,546
  • Annual Sales, $ 0 K
  • Annual Income, $ -101,170 K
  • EBIT $ -26 M
  • EBITDA $ -25 M
  • 60-Month Beta 0.35
  • Price/Sales 109.16
  • Price/Cash Flow N/A
  • Price/Book 1.72
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.61
  • Most Recent Earnings $-0.18 on 11/13/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 334.98% ( +62.70%)
  • Historical Volatility 297.69%
  • IV Percentile 99%
  • IV Rank 86.20%
  • IV High 386.36% on 12/10/24
  • IV Low 14.18% on 09/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 886
  • Volume Avg (30-Day) 2,188
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 44,238
  • Open Int (30-Day) 25,509

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.17
  • Number of Estimates 5
  • High Estimate -0.13
  • Low Estimate -0.19
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -70.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3316 +84.35%
on 11/25/24
0.8761 -30.22%
on 12/11/24
+0.2709 (+79.58%)
since 11/20/24
3-Month
0.2612 +134.04%
on 11/13/24
0.8761 -30.22%
on 12/11/24
-0.0957 (-13.54%)
since 09/20/24
52-Week
0.2612 +134.04%
on 11/13/24
1.6000 -61.79%
on 04/03/24
-0.1188 (-16.27%)
since 12/20/23

Most Recent Stories

More News
X4 Pharmaceuticals to Present Pivotal Phase 3 Trial Data for Mavorixafor at ASH Annual Meeting 2024

X4 Pharmaceuticals announces presentations at the ASH Annual Meeting on mavorixafor for chronic neutropenia treatment.Quiver AI SummaryX4 Pharmaceuticals announced its participation in the 66th American...

XFOR : 0.6113 (+0.66%)
X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

XFOR : 0.6113 (+0.66%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR : 0.6113 (+0.66%)
X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference

XFOR : 0.6113 (+0.66%)
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

XFOR : 0.6113 (+0.66%)
X4 Pharmaceuticals: Q3 Earnings Snapshot

X4 Pharmaceuticals: Q3 Earnings Snapshot

XFOR : 0.6113 (+0.66%)
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

XFOR : 0.6113 (+0.66%)
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

XFOR : 0.6113 (+0.66%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR : 0.6113 (+0.66%)
X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

XFOR : 0.6113 (+0.66%)

Business Summary

X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 0.7773
2nd Resistance Point 0.7286
1st Resistance Point 0.6700
Last Price 0.6113
1st Support Level 0.5627
2nd Support Level 0.5140
3rd Support Level 0.4554

See More

52-Week High 1.6000
Fibonacci 61.8% 1.0886
Fibonacci 50% 0.9306
Fibonacci 38.2% 0.7726
Last Price 0.6113
52-Week Low 0.2612

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar